"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
Becauseofthemildanti-cho-linergic effect of orphenadrine, Orphengesic (orphenadrine citrate, asprin and caffeine tablets) Tablets, or Or-phengesicForteTabletsshould not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostat-ic hypertrophy orobstructions at the bladder neck. Orphen-gesic Tablets or Orphengesic (orphenadrine citrate, asprin and caffeine tablets) Forte Tablets are also contraindicated in patients withmy-astheniagravis and in patients known to be sensitive to aspirin or caffeine.
The drug is contraindicated in patients who have demonstrated a previous hypersensi-tivitytothe drug.
Last reviewed on RxList: 12/17/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Orphengesic Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.